Liraglutide in Adolescents With Type 1 Diabetes

NCT02516657 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of liraglutide, a medication, in adolescents who have type 1 diabetes to see how it affects their average weekly blood glucose levels.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 5 people

Who can join Ages 15–21 · all sexes

Timeline Started 2012-05 · est. completion 2023-08

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02516657 ↗

Description as written by the study sponsor.

The purpose of this study is to study the effect of a liraglutide, a glucagon-like peptide agonist, on post-meal blood glucose concentrations, glucagon levels, mean weekly blood sugars, and insulin doses in adolescents with Type 1 diabetes. Type 1 diabetes is an autoimmune disease that is usually diagnosed before the age of 20. Individuals with this disease are completely dependent on insulin for survival. While significant advances have been made in technological support for improving diabetes control, insulin remains the only effective treatment for Type 1 diabetes. Liraglutide is a long-acting glucagon-like peptide-1 analog. This drug is approved for the treatment of Type 2 diabetes in adults. This study will test the effect of liraglutide on blood sugar control in adolescents with Type 1 diabetes.

Treatments tested

Liraglutide also known as Victoza Drug

Liraglutide 0.6 mg

Main thing measured	Mean Weekly Blood Glucose
Sponsor	University at Buffalo
Conditions studied	Type 1 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02516657 ↗